Gw, no Outrage! is this true?
From the TSC:
"Case in point: Xoma CEO Jack Castello, at his recent shareholder meeting, seemed to imply that rival Biogen's drug, Amevive, could cause patients to fall victim to all sorts of bad things, namely infections, cancers, even AIDS. Now, Castello did not specifically link Amevive with these nasty diseases. But he did talk at length about possible problems that occur when a patient's T-cells, or immune cells, are depleted. And guess what? Amevive works by suppressing, or eliminating, certain types of T-cells."
Has xoma/dna show any advantage for xanelim besides the lack of depletion of lymphocytes?
Do they have any prove of pharmacobiologicals doing that in their mab field? Dna has a very strong Rituxan depleting cells by the tons, are they worry?
Blue don't you love competition? Even if it means Biogen will have the best product and the market?
Yes, it is impressive the lack of lymphocyte depletion (very much impressive) for xanelim, especially for the transplant market, and definitely for the psoriasis one, but those cells are not working anyway they are xombies waiting for resurrection into roaring back clinical problems (minimal if any basis for the last sentence).
Just for Entertaiment purposes (especially the previous mentioned last sentence).
No dysclaimers apply.
What is going on at the xoma club? parlamentary problems?
Please, do not advertise the club more, it is becoming cumbersome to read and follow anything meaningful. Ok, not a cofounder but a loyal lurker. |
